Clinical trial · no report yet · Phase 3
NCT00098475
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
- NCT00098475 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 71 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 71 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- DS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple Myeloma
- Interventions
- Dexamethasone; Laboratory Biomarker Analysis; Lenalidomide; Thalidomide
- Arms
- Arm I (lenalidomide, dexamethasone) · Active comparator
- Arm II (lenalidomide, low-dose dexamethasone) · Experimental
- Arm III (thalidomide, dexamethasone) · Active comparator
- Arm IV (thalidomide, low-dose dexamethasone) · Experimental
- Enrollment
- 452
- Primary outcomes
- Proportion of Patients With Objective Response (First Phase, Step 1)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Nov 3, 2004
- Primary completion
- Nov 30, 2008
- Results posted
- Yes
- Registry record
- NCT00098475 · updated Aug 28, 2026
Publications
linked from the registry- Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, Jelinek DF, Carpten J, Fonseca R. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013 Apr 18;121(16):3147-52. doi: 10.1182/blood-2012-07-443606. Epub 2013 Feb 19. PubMed 23422747
- Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011 Oct 20;118(16):4359-62. doi: 10.1182/blood-2011-03-342089. Epub 2011 Aug 22. PubMed 21860025
- Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010 Jan;11(1):29-37. doi: 10.1016/S1470-2045(09)70284-0. Epub 2009 Oct 21. PubMed 19853510